Preclinical experimental models of drug metabolism and disposition in drug discovery and development

Abstract Drug discovery and development involve the utilization of in vitro and in vivo experimental models. Different models, ranging from test tube experiments to cell cultures, animals, healthy human subjects, and even small numbers of patients that are involved in clinical trials, are used at different stages of drug discovery and development for determination of efficacy and safety. The proper selection and applications of correct models, as well as appropriate data interpretation, are critically important in decision making and successful advancement of drug candidates. In this review, we discuss strategies in the applications of both in vitro and in vivo experimental models of drug metabolism and disposition.

[1]  W. Humphreys,et al.  Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans , 2009, Drug Metabolism and Disposition.

[2]  Hayley S. Brown,et al.  Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.

[3]  H. Kroemer,et al.  Transporter-mediated uptake into cellular compartments , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  D. Nebert,et al.  Role of CYP2A5 and 2G1 in acetaminophen metabolism and toxicity in the olfactory mucosa of the Cyp1a2(-/-) mouse. , 1998, Biochemical pharmacology.

[5]  K. Boudjema,et al.  Effects of hypothermic machine perfusion on rat liver function depending on the route of perfusion. , 2001, Transplantation.

[6]  Jane R Kenny,et al.  Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells , 2009, Drug Metabolism and Disposition.

[7]  高橋 信次.  1)Use of ionizing radiation and radionuclides on human beings for medical research, training, and nonmedical purposes.-Report of a WHO Expert Committee Technical Report Series 611,World Health Organization, Geneva, (1977)-取扱店 丸善, 内容 B6判, 本文3頁, 付録6頁 , 1978 .

[8]  K. Muro,et al.  Regioselective monosulfation and disulfation of the phytoestrogens daidzein and genistein by human liver sulfotransferases. , 2004, Drug metabolism and pharmacokinetics.

[9]  T. Pineau,et al.  Role of CYP2E1 in the Hepatotoxicity of Acetaminophen (*) , 1996, The Journal of Biological Chemistry.

[10]  Qing-Yu Zhang,et al.  Generation of a Mouse Model with a Reversible Hypomorphic Cytochrome P450 Reductase Gene: Utility for Tissue-Specific Rescue of the Reductase Expression, and Insights from a Resultant Mouse Model with Global Suppression of P450 Reductase Expression in Extrahepatic Tissues , 2010, Journal of Pharmacology and Experimental Therapeutics.

[11]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[12]  Zhihua Liu,et al.  Generation and Characterization of a CYP2A13/2B6/2F1-Transgenic Mouse Model , 2012, Drug Metabolism and Disposition.

[13]  Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  Ryoichi Fujiwara,et al.  Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus , 2010, Proceedings of the National Academy of Sciences.

[15]  S. Skaggs,et al.  A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma. , 2006, Journal of pharmacological and toxicological methods.

[16]  Li Di,et al.  Profiling drug-like properties in discovery research. , 2003, Current opinion in chemical biology.

[17]  H. Cui,et al.  Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene , 2003, Journal of Biological Chemistry.

[18]  A. Palmer,et al.  The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. , 2004, IDrugs : the investigational drugs journal.

[19]  J. Sahi.  Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates , 2005, Expert opinion on drug metabolism & toxicology.

[20]  D. Dunbar,et al.  An Intestinal Epithelium-Specific Cytochrome P450 (P450) Reductase-Knockout Mouse Model: Direct Evidence for a Role of Intestinal P450s in First-Pass Clearance of Oral Nifedipine , 2009, Drug Metabolism and Disposition.

[21]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[22]  GLUCURONIDATION AS A MAJOR METABOLIC CLEARANCE PATHWAY OF 14C-LABELED MURAGLITAZAR IN HUMANS: METABOLIC PROFILES IN SUBJECTS WITH OR WITHOUT BILE COLLECTION , 2006, Drug Metabolism and Disposition.

[23]  K. Pang,et al.  Retention of transporter activities in cryopreserved, isolated rat hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J. Schellens,et al.  MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4 , 2005, Drug Metabolism and Disposition.

[25]  Ai-Ming Yu,et al.  THE CYP2E1-HUMANIZED TRANSGENIC MOUSE: ROLE OF CYP2E1 IN ACETAMINOPHEN HEPATOTOXICITY , 2005, Drug Metabolism and Disposition.

[26]  E. Abel,et al.  Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity , 2008, Drug Metabolism and Disposition.

[27]  D W Nebert,et al.  Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Li Di,et al.  Application of pharmaceutical profiling assays for optimization of drug-like properties. , 2005, Current opinion in drug discovery & development.

[29]  F. Gonzalez,et al.  Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[30]  Curtis D. Klaassen,et al.  CASARETT AND DOULL'S TOXICOLOGY , 2013, The Ulster Medical Journal.

[31]  R. M. Lightfoot,et al.  Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. , 1999, The Journal of pharmacology and experimental therapeutics.

[32]  J. Ward,et al.  Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Olinga,et al.  IN VITRO AND EX VIVO TEST SYSTEMS TO RATIONALIZE DRUG DESIGN AND DELIVERY , 1994 .

[34]  Masato Chiba,et al.  Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[35]  Caroline A. Lee,et al.  EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES , 2005, Drug Metabolism and Disposition.

[36]  Nicola J Hewitt,et al.  Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum‐free incubations , 2006, The Journal of pharmacy and pharmacology.

[37]  H. Cui,et al.  In Vivo Mechanisms of Tissue-Selective Drug Toxicity: Effects of Liver-Specific Knockout of the NADPH-Cytochrome P450 Reductase Gene on Acetaminophen Toxicity in Kidney, Lung, and Nasal Mucosa , 2005, Molecular Pharmacology.

[38]  O. Pelkonen.  Biotransformation of xenobiotics in the fetus. , 1980, Pharmacology & therapeutics.

[39]  Qing-Yu Zhang,et al.  Generation and Characterization of a Cyp2f2-Null Mouse and Studies on the Role of CYP2F2 in Naphthalene-Induced Toxicity in the Lung and Nasal Olfactory Mucosa , 2011, Journal of Pharmacology and Experimental Therapeutics.

[40]  L. Gan,et al.  Testing Drug Candidates for CYP3A4 Induction , 2007 .

[41]  F. Gonzalez,et al.  Humanized Mouse Lines and Their Application for Prediction of Human Drug Metabolism and Toxicological Risk Assessment , 2008, Journal of Pharmacology and Experimental Therapeutics.

[42]  C. Wolf,et al.  Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase* , 2003, The Journal of Biological Chemistry.

[43]  D. Nebert,et al.  Oral Benzo[a]pyrene in Cyp1 Knockout Mouse Lines: CYP1A1 Important in Detoxication, CYP1B1 Metabolism Required for Immune Damage Independent of Total-Body Burden and Clearance Rate , 2006, Molecular Pharmacology.

[44]  M. Bayliss,et al.  Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery. , 2000, Drug discovery today.

[45]  R. Riley,et al.  EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES , 2006, Drug Metabolism and Disposition.

[46]  W. Humphreys,et al.  Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans , 2009, Drug Metabolism and Disposition.

[47]  A. Li,et al.  Effects of cytochrome P450 inducers on 17alpha-ethinyloestradiol (EE2) conjugation by primary human hepatocytes. , 1999, British journal of clinical pharmacology.

[48]  W. Humphreys,et al.  Role of CYP2A5 in the Clearance of Nicotine and Cotinine: Insights from Studies on a Cyp2a5-null Mouse Model , 2010, Journal of Pharmacology and Experimental Therapeutics.

[49]  P. Meier,et al.  Isolation and characterization of the putative canalicular bile salt transport system of rat liver. , 1987, The Journal of biological chemistry.

[50]  M. Ingelman-Sundberg,et al.  Generation of Mice Transgenic for Human CYP2C18 and CYP2C19: Characterization of the Sexually Dimorphic Gene and Enzyme Expression , 2008, Drug Metabolism and Disposition.

[51]  P. Lam,et al.  Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs , 2008, Drug Metabolism and Disposition.

[52]  A. Li,et al.  Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. , 1999, Chemico-biological interactions.

[53]  Chuang Lu,et al.  Cytochrome-P450 induction and conjugated metabolism in primary human hepatocytes after cryopreservation , 1997 .

[54]  X. Chu,et al.  Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction , 2008, Drug Metabolism and Disposition.

[55]  Kazuya Maeda,et al.  Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.

[56]  H. Mehendale.  Uptake and disposition of chlorinated biphenyls by isolated perfused rat liver. , 1976, Drug metabolism and disposition: the biological fate of chemicals.

[57]  S. N. Comezoglu,et al.  ADME Studies in Animals and Humans: Experimental Design, Metabolite Profiling and Identification, and Data Presentation , 2007 .

[58]  D. Nebert,et al.  Toward the evaluation of function in genetic variability: Characterizing human SNP frequencies and establishing BAC‐transgenic mice carrying the human CYP1A1_CYP1A2 locus , 2005, Human mutation.

[59]  A. Li,et al.  Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. , 2001, Chemico-biological interactions.

[60]  Li Di,et al.  Pharmaceutical profiling in drug discovery. , 2003, Drug discovery today.

[61]  R. Parker,et al.  Enterohepatic recycling of phenolphthalein, morphine, lysergic acid diethylamide (LSD) and diphenylacetic acid in the rat. Hydrolysis of glucuronic acid conjugates in the gut lumen. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[62]  W. Humphreys,et al.  Comparative Metabolism of Radiolabeled Muraglitazar in Animals and Humans by Quantitative and Qualitative Metabolite Profiling , 2007, Drug Metabolism and Disposition.

[63]  Ji-Ying Song,et al.  Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. , 2007, The Journal of clinical investigation.

[64]  F. Gonzalez,et al.  Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice , 2008, Drug Metabolism and Disposition.

[65]  Bruno Stieger,et al.  Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[66]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[67]  D. Dunbar,et al.  Role of Small Intestinal Cytochromes P450 in the Bioavailability of Oral Nifedipine , 2007, Drug Metabolism and Disposition.

[68]  Chuang Lu,et al.  A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data , 2007, Drug Metabolism and Disposition.

[69]  D. Nebert,et al.  Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. , 2000, Biochemical and biophysical research communications.

[70]  J. Valentin.  Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[71]  J. Idle,et al.  The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. , 2001, Molecular pharmacology.

[72]  Chuang Lu.  Metabolic Stability Screen in Drug Discovery , 2014 .

[73]  R. Obach,et al.  Hydralazine As a Selective Probe Inactivator of Aldehyde Oxidase in Human Hepatocytes: Estimation of the Contribution of Aldehyde Oxidase to Metabolic Clearance , 2012, Drug Metabolism and Disposition.

[74]  P. Swiatek,et al.  Transgenic Mice with a Hypomorphic NADPH-Cytochrome P450 Reductase Gene: Effects on Development, Reproduction, and Microsomal Cytochrome P450 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[75]  Y. Sugiyama,et al.  Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. , 2003, Drug metabolism and pharmacokinetics.

[76]  P. Swiatek,et al.  Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. , 2005, Biochemical and biophysical research communications.

[77]  K. Maeda,et al.  Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[78]  D. Meijer,et al.  THE ISOLATED-PERFUSED RAT-LIVER AS A TOOL TO STUDY DRUG TRANSPORT, DRUG-METABOLISM AND CELL-SPECIFIC DRUG-DELIVERY , 1994 .

[79]  K. Maeda,et al.  The use of hepatocytes to investigate drug uptake transporters. , 2010, Methods in molecular biology.

[80]  R. Edwards,et al.  Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.